We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies, revised Privacy Policy and Terms of Service.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
Copart (CPRT) Q3 Earnings & Sales Miss Estimates, Down Y/Y
Read MoreHide Full Article
Copart, Inc. (CPRT - Free Report) reported third-quarter fiscal 2020 (ended Apr 30, 2020) adjusted earnings per share of 58 cents, missing the Zacks Consensus Estimate of 64 cents. The figure also came in lower than the year-ago number of 66 cents.
Total revenues came in at $550.4 million, missing the Zacks Consensus Estimate of $554 million. The top line also came in 0.5% lower than the year-ago figure of $553.1 million.
Service revenues came in at $491.6 million, up from the $473.7 million recorded in the year-ago quarter. Service revenues accounted for 89.3% of total revenues. Vehicle sales totaled $58.8 million during the quarter, down from the year-ago level of $79.4 million.
Gross profit was down 3.6% year over year to $242.6 million. Total operating expenses flared up to $355.2 million from the $345.6 million incurred in the prior-year period. Operating income decreased to $195.1 million from the $207.5 million reported in the previous year.Net income came in at $147.5 million, down 23.5% from the year-ago figure of $192.7 million. Adjusted net income was $138.2 million in the reported quarter compared with $154.9 million in the prior year quarter.
Copart had cash and cash equivalents of $306.4 million as of Apr 30, 2020, compared with $186.3 million as of Jul 31, 2019. Long-term debt, revolving loan facility and capital-lease obligations were $403.6 million as of Apr 30, 2020, up from $400.1 million as of Jul 31, 2019.
Over the past year, Copart’s shares have increased 33.8% compared with the industry’s rise of 30.1%.
Zacks Rank & Stocks to Consider
Copart currently carries a Zacks Rank of 3 (Hold).
DocuSign has an expected earnings growth rate of 71.89% for the current year. The stock has appreciated 135.1% in the past year.
PFSweb has a projected earnings growth rate of 80% for 2020. The company’s shares have gained 52.6% over the past year.
Energous has an estimated earnings growth rate of 7.1% for the ongoing year. The company’s shares have rallied 18.5% in a year’s time.
Breakout Biotech Stocks with Triple-Digit Profit Potential
The biotech sector is projected to surge beyond $775 billion by 2024 as scientists develop treatments for thousands of diseases. They’re also finding ways to edit the human genome to literally erase our vulnerability to these diseases.
Zacks has just released Century of Biology: 7 Biotech Stocks to Buy Right Now to help investors profit from 7 stocks poised for outperformance. Our recent biotech recommendations have produced gains of +50%, +83% and +164% in as little as 2 months. The stocks in this report could perform even better.
Image: Bigstock
Copart (CPRT) Q3 Earnings & Sales Miss Estimates, Down Y/Y
Copart, Inc. (CPRT - Free Report) reported third-quarter fiscal 2020 (ended Apr 30, 2020) adjusted earnings per share of 58 cents, missing the Zacks Consensus Estimate of 64 cents. The figure also came in lower than the year-ago number of 66 cents.
Copart, Inc. Price, Consensus and EPS Surprise
Copart, Inc. price-consensus-eps-surprise-chart | Copart, Inc. Quote
Total revenues came in at $550.4 million, missing the Zacks Consensus Estimate of $554 million. The top line also came in 0.5% lower than the year-ago figure of $553.1 million.
Service revenues came in at $491.6 million, up from the $473.7 million recorded in the year-ago quarter. Service revenues accounted for 89.3% of total revenues. Vehicle sales totaled $58.8 million during the quarter, down from the year-ago level of $79.4 million.
Gross profit was down 3.6% year over year to $242.6 million. Total operating expenses flared up to $355.2 million from the $345.6 million incurred in the prior-year period. Operating income decreased to $195.1 million from the $207.5 million reported in the previous year.Net income came in at $147.5 million, down 23.5% from the year-ago figure of $192.7 million. Adjusted net income was $138.2 million in the reported quarter compared with $154.9 million in the prior year quarter.
Copart had cash and cash equivalents of $306.4 million as of Apr 30, 2020, compared with $186.3 million as of Jul 31, 2019. Long-term debt, revolving loan facility and capital-lease obligations were $403.6 million as of Apr 30, 2020, up from $400.1 million as of Jul 31, 2019.
Over the past year, Copart’s shares have increased 33.8% compared with the industry’s rise of 30.1%.
Zacks Rank & Stocks to Consider
Copart currently carries a Zacks Rank of 3 (Hold).
Some better-ranked stocks in the same sector are DocuSign Inc. (DOCU - Free Report) , PFSweb, Inc. and SPS Commerce, Inc. (SPSC - Free Report) , each carrying a Zacks Rank of 2 (Buy) at present. You can see the complete list of today’s Zacks #1 Rank (Strong Buy) stocks here.
DocuSign has an expected earnings growth rate of 71.89% for the current year. The stock has appreciated 135.1% in the past year.
PFSweb has a projected earnings growth rate of 80% for 2020. The company’s shares have gained 52.6% over the past year.
Energous has an estimated earnings growth rate of 7.1% for the ongoing year. The company’s shares have rallied 18.5% in a year’s time.
Breakout Biotech Stocks with Triple-Digit Profit Potential
The biotech sector is projected to surge beyond $775 billion by 2024 as scientists develop treatments for thousands of diseases. They’re also finding ways to edit the human genome to literally erase our vulnerability to these diseases.
Zacks has just released Century of Biology: 7 Biotech Stocks to Buy Right Now to help investors profit from 7 stocks poised for outperformance. Our recent biotech recommendations have produced gains of +50%, +83% and +164% in as little as 2 months. The stocks in this report could perform even better.
See these 7 breakthrough stocks now>>